Ono Pharmaceutical Future Growth
Future criteria checks 0/6
Ono Pharmaceutical's revenue and earnings are forecast to decline at 0.2% and 5.2% per annum respectively. EPS is expected to decline by 4.6% per annum. Return on equity is forecast to be 12.4% in 3 years.
Key information
-5.2%
Earnings growth rate
-4.6%
EPS growth rate
Pharmaceuticals earnings growth | 19.6% |
Revenue growth rate | -0.2% |
Future return on equity | 12.4% |
Analyst coverage | Good |
Last updated | 12 Jan 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 504,111 | 119,759 | 116,144 | 138,913 | 12 |
3/31/2025 | 487,689 | 113,178 | 113,483 | 137,110 | 13 |
3/31/2024 | 502,112 | 131,421 | 123,789 | 141,086 | 13 |
9/30/2023 | 489,199 | 124,875 | 97,371 | 115,354 | N/A |
6/30/2023 | 460,481 | 115,064 | 98,429 | 116,894 | N/A |
3/31/2023 | 447,187 | 112,723 | 145,113 | 159,610 | N/A |
12/31/2022 | 428,951 | 111,555 | 137,391 | 149,495 | N/A |
9/30/2022 | 403,985 | 96,568 | 93,387 | 102,437 | N/A |
6/30/2022 | 380,720 | 85,922 | 78,395 | 88,151 | N/A |
3/31/2022 | 361,361 | 80,519 | 49,552 | 61,829 | N/A |
12/31/2021 | 345,781 | 73,558 | 38,233 | 53,343 | N/A |
9/30/2021 | 332,887 | 81,866 | 60,412 | 83,032 | N/A |
6/30/2021 | 321,734 | 78,003 | 47,401 | 70,321 | N/A |
3/31/2021 | 309,284 | 75,425 | 53,684 | 73,977 | N/A |
12/31/2020 | 302,054 | 74,364 | 53,088 | 72,011 | N/A |
9/30/2020 | 293,886 | 66,737 | 55,742 | 70,596 | N/A |
6/30/2020 | 293,351 | 64,870 | 58,824 | 78,232 | N/A |
3/31/2020 | 292,420 | 59,704 | 51,712 | 74,157 | N/A |
12/31/2019 | 290,736 | 60,233 | 43,202 | 73,947 | N/A |
9/30/2019 | 293,247 | 55,510 | 38,797 | 66,058 | N/A |
6/30/2019 | 291,374 | 52,633 | 32,152 | 58,850 | N/A |
3/31/2019 | 288,634 | 51,539 | 37,172 | 66,774 | N/A |
12/31/2018 | 284,463 | 51,978 | 42,500 | 67,269 | N/A |
9/30/2018 | 284,785 | 57,919 | 29,645 | 61,700 | N/A |
6/30/2018 | 272,165 | 53,746 | 16,591 | 48,716 | N/A |
3/31/2018 | 261,836 | 50,284 | -14,111 | 15,727 | N/A |
12/31/2017 | 256,522 | 54,760 | 1,151 | 28,754 | N/A |
9/30/2017 | 248,517 | 53,884 | 19,296 | 40,205 | N/A |
6/30/2017 | 246,953 | 53,887 | N/A | 53,650 | N/A |
3/31/2017 | 244,797 | 55,793 | N/A | 74,450 | N/A |
12/31/2016 | 236,710 | 48,270 | N/A | 44,743 | N/A |
9/30/2016 | 207,707 | 36,225 | N/A | 32,972 | N/A |
6/30/2016 | 183,345 | 29,206 | N/A | 16,805 | N/A |
3/31/2016 | 160,284 | 24,979 | N/A | 12,842 | N/A |
12/31/2015 | 140,927 | 16,449 | N/A | 29,716 | N/A |
9/30/2015 | 143,697 | 21,568 | N/A | 31,169 | N/A |
6/30/2015 | 139,663 | 19,521 | N/A | 30,488 | N/A |
3/31/2015 | 135,775 | 12,976 | N/A | 31,579 | N/A |
12/31/2014 | 137,592 | 17,663 | N/A | N/A | N/A |
9/30/2014 | 133,926 | 13,474 | N/A | 19,681 | N/A |
6/30/2014 | 137,146 | 16,787 | N/A | N/A | N/A |
3/31/2014 | 143,247 | 20,350 | N/A | 28,422 | N/A |
12/31/2013 | 145,946 | 21,574 | N/A | N/A | N/A |
9/30/2013 | 145,984 | 23,205 | N/A | 18,773 | N/A |
6/30/2013 | 145,650 | 22,170 | N/A | N/A | N/A |
3/31/2013 | 145,393 | 24,120 | N/A | 15,662 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4528 N's earnings are forecast to decline over the next 3 years (-5.2% per year).
Earnings vs Market: 4528 N's earnings are forecast to decline over the next 3 years (-5.2% per year).
High Growth Earnings: 4528 N's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 4528 N's revenue is expected to decline over the next 3 years (-0.2% per year).
High Growth Revenue: 4528 N's revenue is forecast to decline over the next 3 years (-0.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4528 N's Return on Equity is forecast to be low in 3 years time (12.4%).